Apricitabine
is an experimental nucleoside reverse transcriptase inhibitor (NRTI).
Apricitabine
is being developed by Avexa, an Australian pharmaceutical company. The drug was
first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma
was then sold the Shire Pharmaceuticals (where the drug was called SPD754). Shire
then sold the rights to develop the drug to Avexa.